Pancreatic Cancer Research

ResearcherTokyo University of Pharmacy and Life SciencesActive in the last 2 years

Ken-ichi Suzuki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4682-4369; OpenAlex author ID A5101725236. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 2 papers

Papers 3

  1. Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. Last author DOI 10.1002/bcp.70611↗
  2. Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-026-03201-0↗
  3. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT s… Co-author DOI 10.1002/cncr.35343↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daiki Tsuji · 3 shared papers, 2024–2026 · strength 0.63
  2. Takashi Yokokawa · 3 shared papers, 2024–2026 · strength 0.63
  3. Hiroshi Ishii · 3 shared papers, 2024–2026 · strength 0.63
  4. Masahiro Hatori · 3 shared papers, 2024–2026 · strength 0.63
  5. Kunihiko Itoh · 3 shared papers, 2024–2026 · strength 0.63
  6. Naoki Sasahira · 3 shared papers, 2024–2026 · strength 0.63
  7. Masato Ozaka · 2 shared papers, 2026 · strength 0.47
  8. Aki Otake · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.